1. Home
  2. MHF vs SPRO Comparison

MHF vs SPRO Comparison

Compare MHF & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Municipal High Income Fund Inc.

MHF

Western Asset Municipal High Income Fund Inc.

HOLD

Current Price

$7.03

Market Cap

153.1M

Sector

Finance

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.22

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MHF
SPRO
Founded
1988
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.1M
156.3M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
MHF
SPRO
Price
$7.03
$2.22
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
73.7K
1.6M
Earning Date
01-01-0001
05-13-2026
Dividend Yield
4.29%
N/A
EPS Growth
N/A
111.81
EPS
N/A
N/A
Revenue
N/A
$66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$300.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
39.24
52 Week Low
$6.61
$1.80
52 Week High
$7.64
$3.08

Technical Indicators

Market Signals
Indicator
MHF
SPRO
Relative Strength Index (RSI) 58.39 41.58
Support Level $6.84 $2.12
Resistance Level $7.05 $2.50
Average True Range (ATR) 0.09 0.24
MACD 0.01 -0.04
Stochastic Oscillator 51.32 25.00

Price Performance

Historical Comparison
MHF
SPRO

About MHF Western Asset Municipal High Income Fund Inc.

Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: